Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Denton

Showing results (251-260 of 607) with videos related to

Pageof 61
Sort By:
Clinical and Experimental Rheumatology|August 4, 2025
Impact of immunosuppression on development and outcome of systemic sclerosis-associated pulmonary arterial hypertensionStefano Rodolfi, Cheryl Chun Man Ng, Ana Maria Ruiz Bejerano, et al.
The European Respiratory Journal|August 29, 2024
Definition, classification and diagnosis of pulmonary hypertensionGabor Kovacs, Sonja Bartolome, Christopher P Denton, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 19, 2022
Dynamic Prediction of Pulmonary Hypertension in Systemic Sclerosis Using Landmark AnalysisSvetlana I Nihtyanova, Benjamin E Schreiber, Voon H Ong, et al.
British Journal of Rheumatology|February 1, 1997
Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosisC P Denton, J B Cailes, G D Phillips, et al.
Annals of the Rheumatic Diseases|January 17, 2012
Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO RegistryChristopher P Denton, Thomas Krieg, Loic Guillevin, et al.
Rheumatology (Oxford, England)|September 19, 2001
Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetineB Coleiro, S E Marshall, C P Denton, et al.
Annals of the Rheumatic Diseases|November 18, 2004
The myth of pulmonary Raynaud's phenomenon: the contribution of pulmonary arterial vasospasm in patients with systemic sclerosis related pulmonary arterial hypertensionD Mukerjee, L B Yap, V Ong, et al.
Arthritis and Rheumatism|April 1, 2006
Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblastsYunliang Chen, Xu Shi-wen, Mark Eastwood, et al.
QJM : Monthly Journal of the Association of Physicians|December 8, 2009
Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort studyS I Nihtyanova, E C Tang, J G Coghlan, et al.
British Journal of Pharmacology|June 1, 1978
Levels of prostaglandins and their precursors in EFA-deficient rabbits--a new concept of prostaglandin biosynthesis [proceedings]M A Crawford, J P Denton, A G Hassam, et al.
Pageof 61

Showing results (251-260 of 607) with videos related to

Sort By:
Pageof 61
Clinical and Experimental Rheumatology|August 4, 2025
Impact of immunosuppression on development and outcome of systemic sclerosis-associated pulmonary arterial hypertensionStefano Rodolfi, Cheryl Chun Man Ng, Ana Maria Ruiz Bejerano, et al.
The European Respiratory Journal|August 29, 2024
Definition, classification and diagnosis of pulmonary hypertensionGabor Kovacs, Sonja Bartolome, Christopher P Denton, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 19, 2022
Dynamic Prediction of Pulmonary Hypertension in Systemic Sclerosis Using Landmark AnalysisSvetlana I Nihtyanova, Benjamin E Schreiber, Voon H Ong, et al.
British Journal of Rheumatology|February 1, 1997
Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosisC P Denton, J B Cailes, G D Phillips, et al.
Annals of the Rheumatic Diseases|January 17, 2012
Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO RegistryChristopher P Denton, Thomas Krieg, Loic Guillevin, et al.
Rheumatology (Oxford, England)|September 19, 2001
Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetineB Coleiro, S E Marshall, C P Denton, et al.
Annals of the Rheumatic Diseases|November 18, 2004
The myth of pulmonary Raynaud's phenomenon: the contribution of pulmonary arterial vasospasm in patients with systemic sclerosis related pulmonary arterial hypertensionD Mukerjee, L B Yap, V Ong, et al.
Arthritis and Rheumatism|April 1, 2006
Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblastsYunliang Chen, Xu Shi-wen, Mark Eastwood, et al.
QJM : Monthly Journal of the Association of Physicians|December 8, 2009
Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort studyS I Nihtyanova, E C Tang, J G Coghlan, et al.
British Journal of Pharmacology|June 1, 1978
Levels of prostaglandins and their precursors in EFA-deficient rabbits--a new concept of prostaglandin biosynthesis [proceedings]M A Crawford, J P Denton, A G Hassam, et al.
Pageof 61